Initiated Daxdilimab Discoid Lupus Erythematosus Phase 2 Trial, HZN-457 Gout Phase 1 Trial and ADX-914 Atopic Dermatitis Phase 2 Trial in Collaboration with Q32 Bio -ĭUBLIN-(BUSINESS WIRE)-Horizon Therapeutics plc (Nasdaq: HZNP) today announced fourth-quarter and record full-year 2022 financial results. Received Approval for UPLIZNA in Brazil for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder. Expect to Initiate TEPEZZA Phase 3 Trial in Japan in Chronic/Low CAS TED in 2023. TEPEZZA Chronic/Low Clinical Activity Score (CAS) TED Trial in 2Q23. Completed Enrollment in TEPEZZA Phase 3 Trial in Japan (OPTIC-J) in Active Thyroid Eye Disease (TED) Topline Results Expected in 3Q23. Announced Positive Topline Data from the Second Population in Dazodalibep Sjögren’s Syndrome Phase 2 Trial First and Only Phase 2 Sjögren’s Syndrome Trial to Meet the Primary Endpoint in Both Patient Populations Phase 3 Clinical Program Expected to Initiate in 2023. Entered into Agreement to Be Acquired by Amgen Inc. 31, 2022 -įourth-Quarter and Recent Company Highlights: Cash Position of $2.35 Billion as of Dec. Record Operating Cash Flow of $1.26 Billion. Record UPLIZNA Net Sales of $154.6 Million Year-Over-Year Increase of 154%. Record KRYSTEXXA Net Sales of $716.2 Million Year-Over-Year Increase of 27%. Record TEPEZZA Net Sales of $1.97 Billion Year-Over-Year Increase of 18%. GAAP Net Income of $521.5 Million Record Adjusted EBITDA of $1.37 Billion Includes $56.3 Million of Acquired IPR&D and Milestones Expenses. Record Net Sales of $3.63 Billion Year-Over-Year Increase of 12%. UPLIZNA ® (inebilizumab-cdon) Net Sales of $41.8 Million. KRYSTEXXA ® (pegloticase injection) Net Sales of $216.1 Million. TEPEZZA ® (teprotumumab-trbw) Net Sales of $493.5 Million. GAAP Net Income of $120.4 Million Adjusted EBITDA of $ 357.5 Million Includes $37.3 Million of Acquired IPR&D and Milestones Expenses.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |